277 related articles for article (PubMed ID: 25213036)
21. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
22. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
23. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
24. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F
Ann Oncol; 2017 Sep; 28(9):2241-2247. PubMed ID: 28911085
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.
O'Shaughnessy J; Cortes J; Twelves C; Goldstein LJ; Alexis K; Xie R; Barrios C; Ueno T
Sci Rep; 2020 Jul; 10(1):11203. PubMed ID: 32641747
[TBL] [Abstract][Full Text] [Related]
26. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
27. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
Greenhalgh J; Bagust A; Boland A; Blundell M; Oyee J; Beale S; Dundar Y; Hockenhull J; Proudlove C; Chu P
Pharmacoeconomics; 2013 May; 31(5):403-13. PubMed ID: 23576017
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.
Bagust A; Greenhalgh J; Boland A; Fleeman N; McLeod C; Dickson R; Dundar Y; Proudlove C; Shaw R
Pharmacoeconomics; 2010; 28(6):439-48. PubMed ID: 20465313
[TBL] [Abstract][Full Text] [Related]
29. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
Ramaswami R; O'Cathail SM; Brindley JH; Silcocks P; Mahmoud S; Palmieri C
Future Oncol; 2014 Feb; 10(3):363-76. PubMed ID: 24367990
[TBL] [Abstract][Full Text] [Related]
30. An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
Pouwels XGLV; Ramaekers BLT; Geurts SME; Erdkamp F; Vriens BEPJ; Aaldering KNA; van de Wouw AJ; Dercksen MW; Smilde TJ; Peters NAJB; van Riel JMGH; Pepels MJ; Heijnen-Mommers J; Tjan-Heijnen VCG; de Boer M; Joore MA
Acta Oncol; 2020 Sep; 59(9):1123-1130. PubMed ID: 32544366
[No Abstract] [Full Text] [Related]
31. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
33. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
34. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
35. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
36. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
37. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.
Kearns B; Lloyd Jones M; Stevenson M; Littlewood C
Pharmacoeconomics; 2013 Jun; 31(6):479-88. PubMed ID: 23580356
[TBL] [Abstract][Full Text] [Related]
38. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
[TBL] [Abstract][Full Text] [Related]
39. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
